Sygnature Discovery

JUNE 17, 2024

From hit finding and target engagement studies, to the characterisation of kinetic properties for late-stage candidate molecules, we believe that a biophysical approach complements other assays to deliver a fuller picture of binding behaviour to produce more effective therapeutics.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

Drug Target Review

NOVEMBER 1, 2023

Capivasertib originated from a collaboration between my former company Astex Pharmaceuticals and the ICR and was further developed by AstraZeneca. In 2001, he joined Astex Pharmaceuticals in Cambridge where he became an expert in fragment-based drug discovery working on diabetes, thrombotic and oncology drug targets.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Drug Target Review

JANUARY 16, 2025

Their collaborative work continues to drive advancements in computational methods, offering new solutions to the intricate problems of preclinical pharmaceutical discovery through innovative predictive modelling techniques. Pharmaceuticals , 16(7):996, 2023. References Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Springer, 2019.

Drug Development 52

Drug Development Small Molecule Drugs FDA Approval 52